TNYA – tenaya therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $18.00 price target on the stock.
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy [Yahoo! Finance]
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 [Yahoo! Finance]
Form 8-K Tenaya Therapeutics, For: Dec 17
Form 8-K Tenaya Therapeutics, For: Dec 16
Form 4 Tenaya Therapeutics, For: Nov 18 Filed by: Saito Chihiro
Form SC 13G/A Tenaya Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SC 13G/A Tenaya Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.